- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Following managements' prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 8, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. ahead. go Please

Jessica Serra

Daniel. Thank you,

on Executive the Chief Revance us today Officer, call Mark Foley; Chief Officer, and Schilke. are President, Toby Joining from Dustin Financial Sjuts;

statements compete, will During breakeven, call, economic and effectively future cash capital blockbuster our of behavior, us, and and make our related of to consumers preferences to debt, our operations our potential, timing. plans allocation planned our benefits capital supply and business and forward-looking and approvals, strategy, ability to this expenditures the and consumer to growth draw our management on DAXXIFY, ability plans, flow the statements, practices headwinds and our and conference manufacture the commercialization products, our submissions impact and regulatory guidance, including of consumers on XXXX

Revance. on Form X, and or Our Revance statements to Foley, timing the different With a expectations. uncertainties. November in from our section to turn cause could to call SEC XX-Q those statements differ will the the Company of results the in events Mark? quarterly Factors these in materially duty Risk of of future as forward-looking of Chief include no over such as titled factors risks Mark these changes and statements forward-looking could with update any result new result in actual its today, obligation a anticipated report Executive undertakes information, XXXX. Factors or describes filed events that, Officer results that from the be I

Mark Foley

our conference third everyone, and afternoon, results you quarter financial XXXX Jessica. joining for call. you, Good Thank thank

This the approval injectables $XXX us closed only foundation positions balance an this for year a for inflection for first We're strength. which Further, the facial we the our also our Company offering, for dystonia, us the to glabellar significant follow-on our indication. aesthetics U.S. formulated providing neuromodulator therapeutic first long-acting launch and and a cervical submission milestone million third positions lines. of will as our and the in to position realize approval, DAXXIFY innovation given DAXXIFY, Revance from blockbuster in point The potential market. leader sheet of of the peptide bolstered marked sBLA quarter FDA's DAXXIFY's enable upon

The third quarter of from revenue commercial a delivered $XX.X XX% RHA a was year-over-year million, representing also broader despite as standpoint strong increase factors. record economic we

all quarter Enthusiasm later launch very Redensity, reflected growth Our over market for our call. successful evidenced from RHA the solid key have approval, by and the continues impressions in earned highlighted media proposition continue injectors of formulation the countless to DAXXIFY to the X.X consumers. and cover the DAXXIFY's will Dustin peptide performance in drivers inquiries as be share strong receive with value XX-week along interest. of median continued billion which from strong, unique duration, post we as and been

advance that produces California FDA's in site building inventory Aji Biopharma San in the the is dual our supply Prior approval market. site or Approval DAXXIFY We that of wholly-owned Newark, for building a and drug XXXX. substance already have on of we encouraged for are to filed believe California. adoption Progress Diego, drug engagement facility been chain support, of PAS by approval. well and based we this We that source of anticipate our as inventory, uptake will acceptance and bode upon product, and FDA's is FDA-approved also bring launch. in and level manufacturing of recently that we Recall we and the received both Ajinomoto to manufacturer, Supplement high which the our in in Aji, Fill/Finish at we've process product very contract or made prepare

and capacity we well-positioned production inventory, believe execute we our existing Aji's Newark's to launch between are anticipated strategy. on approval, So

additional manufacturer of we production an as our place in to which our as with decrease an volume longer-term online needs, Services time. Additionally, DAXXIFY's capacity. enhance and our have goods CMOs New Lyophilization we come expect will cost England increases, And meaningfully agreement of contract our over support or LSNE, to

standard was Beyond about in have treating that is Phase is XX not and beginning the the X week XX. a disabling signs reducing generally while talked our patients dystonia. duration In payers allowed symptoms and painful Neuromodulators care long neck. of cervical effective the and with well-tolerated providing weeks. a the Cervical dystonia clinical to in DAXXIFY for opportunity by safe prior cervical that of dystonia and DAXXIFY's effect trial XX of aesthetics, muscles cervical are we demonstrated compelling condition therapeutics, median dystonia it retreatment and affects of yet to

XX symptoms patients In of fact, peer-reviewed Cervical X,XXX the with reemergence countries, between survey that revealed of Patients results Journal of treatment time notably, was Dystonia a of International published Survey titled the in about the XX.X experienced a weeks. to sessions. of over article XX% in which Neurology, An from reemergence And symptom patients reported mean

recurrence provide result, a week DAXXIFY's a effect. clinical potential market represent and to and treatment patients benefits and manage care prior treatment current providers As bringing profile on Based CD patients We have significant pharmacoeconomic option. differentiated providing to DAXXIFY for could forward to without landscape, the payers. patients, to who in to with compelling XX to the advance look have an symptom important

glabellar finalize of DAXXIFY cervical to worked sBLA our for we Following for dystonia. the approval hard submit and lines,

program, ASPEN-X which Our submission studies. ASPEN-OLS clinical from is our by the supported data X and ASPEN Phase included development

are for forward largest dystonia followed at is allowing nearly represents if tremendous for therapeutics, be within size In disorder includes which $X.X the sits across U.S. U.S. neuromodulators migraine. to billion foundation over aesthetics by look value total our market, The to in billion. $X neuromodulator We short the and market, and approved, both unlocked therapeutic therapeutic and muscle into about date DAXXIFY market category DAXXIFY This cervical innovation movement single XXXX time. also a opportunity launching spasticity. anticipating PDUFA the

I an call third clinical to set for aesthetics. Dustin, in medical launch, Dustin? to development, quarter. we our and program. and also overseeing following role our is welcome Chief to timing our affairs. operational He commercial Before broad someone who science, therapeutics will Medical DAXXIFY's will be with affairs, proven Dustin, over pharmacovigilance cervical the I'll Botox experience with guiding will Officer, call familiarity cover sBLA the toxins regulatory both With eyes on scientific I'd who strong regulatory our and innovation, program as data over strategy David and and a biosimilar David turn play as like David has international the to in turn filing performance our executive Hollander contributor a important dystonia. our that,

Dustin Sjuts

we very portfolio. quarter, of proud line our In expanded in for account aesthetic for I'm getting third our our Mark. achieving you, with addition priority the services RHA highly of anticipated team the to of growth preparing key DAXXIFY increased aesthetics approved our DAXXIFY. products in of Thank and driving accounts market, launch top over to across all X,XXX, brought parallel productivity Redensity and in

our X $XX.X from of Recall as the normally up and quarters the sales, healthy marketing good basis, unique from education prior TEOXANE and sales seasonality. Redensity as year-over-year anticipate meet are both line. and indications to that conducted SA, includes valuable our in needs new a existing result, in sequential results to headwinds has our is On our traditional HA of broader providers. targeted that, resulted to We demonstrate continue part X% particularly August, efforts introducing very well, quarter. and our RHA aesthetic that gain programs which the as impact we XX% a focused of we product saw all top start and launch with Combined are achieving with embraced consumers practices. Redensity the and in formulations of were evolving consumers QX be pleased expanding and a the introduced as supported to despite X, context, nationwide down solid rheologic QX and strong uptick partnership are a a by RHA consistent that training positive Collection, well off RHA And with and these share across portfolio multiple are and into initiatives, number injectors a a the representing differentiated that Overall, Put X, sales injectors. across QX properties economic to being see typically We're Our that million proven from seasonality. as increase. product's despite RHA ability and to with and slower feedback reach.

and OPUL, we've counter and our differentiated portfolio, the where DAXXIFY. fit on Collection, programs foundation our RHA $X.X some suite of believe the and could bullish a long-term of and force into have market, injectables In potential compelling services aesthetics we the as partners remain built U.S. proven the and at sales with DAXXIFY, a facial opportunity. growth importantly, this practice which products of competitors. includes we bundling RHA of billion elite of innovative solid ready launch We to XXX-plus looking a we Additionally, that larger

Financial during the market severe cannot 'XX this the we Crisis, impact single digits while recovery. neuromodulator worldwide First, digits been the dermal a low double of before resilient. 'XX, and historically sales in in predict the V-shaped declined demonstrating low has Even fillers environment, current economic

have despite our track past And and prestige resilient given business two-plus that the strategy launch to economic facial our benefit the uniquely particularly, our supporting strategy, the and target neuromodulator To-date, focus commercial are are belief launching neuromodulator. and amongst evident including And are COVID-XX injectable yet our the we RHA us from market measured segment solid resilient of on believe looking an macro by disrupt of challenging model over our we pandemic. the headwinds. our record we commercial are by a to in has that spending. volumes our we Second, a on approach level current growth impacts, finally, our without the guided the consumers anticipated in highly since This launch. is positioned that accounts discretionary insulate years with to innovation we is we impact the proven with seen our most calling for believe potential on, not

our that very launch have We me DAXXIFY. in turn are giving ours meaningful the disruptive let us innovations by said, to that will excitement DAXXIFY, confidence the for With preparations market. like encouraged a the impact for

off noted, to XXXX. experience to partners December we As forward it to broad kicking run previously We're headquarters early of expect group QX of and at plan launch. program through looking initiate in commercial PrevU, national select to with we a program practice our this prior our

practice Following offer our this, to partners. elite to DAXXIFY we existing plan

hosted PrevU accounts trained our our team, months, commercial the the we've for for DAXXIFY Over sessions. few PrevU live our the faculty upcoming full enrolled meeting with past training launch and

this innovative to approach for consistent with of DAXXIFY program educating has on The to thoughtful focused PrevU been a taking purpose on DAXXIFY, of is while are real-world aesthetic gaining we SAKURA while valuable demonstrated launching formulation Phase in that our not reminder, for RHA. injectors applications clinical PrevU duration a to As is and DAXXIFY's insights our outcomes. strategy is the X optimizing validate

allows launch alongside Revance the rest the In seamlessly and tools us training foundation will addition, right DAXXIFY's believe to approach them practices to We category the success. integrate long-term for of this of help set the commercial necessary portfolio. all neuromodulator provide to aesthetics new our PrevU ensure holistic PrevU and of

as to processing Turning the QX progress Gross capabilities adding trailing new loyalty to $XXX up make executing I'm On the third membership our $XXX summary, OPUL; and In accounts, quarter, to drive us is of of quarter. and our program. customers pleased customer growth at we a basis, GPV GPV PrevU up end In year-over-year. building upon the very for our was million as over million, practice deeper in XX.X% RHA opportunities fourth or the Collection quarter, with legacy ahead. migrating for XX-month OPUL penetration volume execution the setting platform. continue the significant focus HintMD the totaled to well

initiatives, broader neuromodulator. that, a optimizing on aesthetic novel I'll financials. to the live PrevU variety With practice virtual commercial call outcomes cover will centered from and two training we with Toby this offer options key integration of turn our we over our third and to As to launch, move quarter

Tobin Schilke

revenue million by in Revenue sales primarily $XX revenue Total of quarter product increased Collection. XX.X% Dustin. RHA driven million $X $XX.X of to service the the third same quarter period included and collaboration Thank million third XXXX you, XXXX revenue. from $X in of revenue, increased the million, the of approximately for of

$XX.X third our quarter operating to period million execute we Turning compared for to the last priority expenses; capital corporate on were operating of million continue the our to year. for $XXX.X allocation. expenses disciplined GAAP same

commercialization $XX.X the non-GAAP and of were higher to a R&D amortization dermal DAXXIFY until period to approved. related depreciation, Recall our increase of expenses have fillers expenses costs is and the manufacturing SG&A year Excluding we stock-based to X% according due to DAXXIFY. expensing the RHA cost related GAAP as been expenses the to related that Collection last same an over million, compensation, operating product

began costs. our approval we the Following in Newark September, manufacturing capitalizing

months the XXXX, compared expenses consolidated primarily to the three September and inventory period of DAXXIFY quality decreased the ended on For the in XXXX, XX, due condensed same to capitalization costs balance sheet. manufacturing

guidance million, and expect of XXX of million upper in approval December, to PrevU program of post pull previously investments and $XXX non-GAAP be million ramp-up ranges the the end $XXX expenses forward commercial GAAP respectively. on As of to to DAXXIFY a result $XXX we our the and our announced operating to

our growth cash position upsized proceeds. successful enhanced offering demand The in stock to the follow-on even view times of plan and use advancement DAXXIFY, We Collection aesthetic our proceeds begin innovation $XXX sheet; stock allocation grounded of with our of and DAXXIFY in applications. to the million net a million FDA commercialization to fund both OPUL therapeutic program. very Turning under were commercial heels of of common the approval our raised reflection of continued We uncertain strong therapeutics to capital our we as X.X RHA economic investors' of the our have for million conviction shares of the $XXX.X to that offering. focus on story in is in the disciplined balance pleased on a growth an principally with offering by the

and withholding which issuance equivalents cash $XXX investments to to fully were to balance, our a RHA cash believe With September of DAXXIFY, the Pharma. for of foreign DAXXIFY and fund Capital from and XX, approval our cash, of to be anticipated includes through related million and notes we the taxes OPUL received of quarter, $X Subsequent portfolio, FDA available breakeven. we additional million Athyrium we U.S. XXXX, Fosun able short-term expenditures, million. revenues our total payment as aesthetics milestone before flow the Our will $XXX.X cash

the And Mark. back call Revance's Finally, turn outstanding as of October with stock that, million convertible impact I'll of XX.X shares of shares, $XX.X were approximately XXXX, debt. million XX, common diluted with excluding to the fully over

Mark Foley

Thank you, organization incredibly our conclude, enhance to for will of I'm great Revance proud delivering a name Toby. the and approval DAXXIFY's entire FDA launch. securing on To addition in a great that label

on commercialization we impressed Additionally, to for I We remain and continue that, you the that DAXXIFY for up potential innovative look growth. I the quarter. questions. people including third and updating will ongoing our now our the drive right to expansion call, in forward led participating continued to commercial on you label today's our open I to Operator? our I cervical Thank execution strategy that forward for call convinced sustainable progress. our results be revenue leverage look all of dystonia. have and place momentum, the products and With excellent with for to

Operator

our [Operator with question first Instructions] comes Sachs. Chris Goldman from And Shibutani

Chris Shibutani

Great. Very good you're the to on much the helpful hear so progress update about that and of making.

pace a are us understand could lot look think what trying the and like. of recovery a tone of I to

we different, maybe V-shape resilient Prestige proxy, about thinking down? using trading how bit from and the framed the that procedure you and that shape on are or targeting can And if drove recovery well of during we recovery? XXXX recession. What a a times. us aesthetics I more and with the consistently about element think you affect Was that are that's similar challenging patterns that recoveries? with should of forward up, something economic an the the you've primarily could as seeing particularly those trading had little trajectory reflect distinctly expect there But volumes here, the to historical the you're markets help segment

Mark Foley

Yes, Chris, this Mark. is

there you being in spend not procedures consumers in at downturn was of What's there clearly, the to prepared that affecting the stated the now in there's calling we're right doubt are by willing is the factors that seeing Financial in we consumer. that So remarks, now those right But the look that our just was environment. a we're macroeconomic in XXXX-XXXX number challenged accounts influenced on. if no reduction not as Crisis,

hard today's an rebound it's now, for we're impact speculate what look So us of right seeing sort to like given in potential market. that the not might

not with, services got the and strategy, it made still really are that across to all phase decision do we're a in accounts discounting less wouldn't that's into and they've that market. prestige different our customers that a be launch likely of commitment products say more and But going think targeting platforms. Now to we've experience of And was forward. product that those there practice. our we're bringing there the with to again, we some innovative for has our this We're going go where higher-end a couponing because I and

hard So might currently that accounts a what on. seeing on us potential the it's for look recovery to-date impact calling given that an like we're we're in speculate to really not

Operator

Cacciatore with our And question comes Cowen. from next Ken

Ken Cacciatore

Congratulations forward. to everything on continuing move

very, you're a this clinicians on, broaden on I give I Just just trained to XXXX? of and many will launch, that. there's wanted be sense just enter looking know the December. you peaceful very we clinicians us way to that, taking lot a you're specifically wondering, know you're in and Can I ask that when how approach starting to but going then a train the

we in-house more of from clinicians, think might the you of about to you talk of we're just substantially that to kind X,XXX when think through personal be a we can give is moving transitioning when if may And when this that going to sense point to level that can forward? then of you have, DAXXIFY X,XXX of fully accounts occur? kind the the broadening launch be initial I training what should next also at

Mark Foley

Ken. in did And our initially would in we for then then DAXXIFY. limited be commercial commentary, we around we're our Yes. launch start plans we QX launch tried consistent pretty plan said the RHA QX is Thanks, of very that in broader that controlled launch. a we prior the launch. commentary to the we of in we our about pulling beginning talked with where In And launch expand And limited comments, We've and same commercial PrevU launch. following we would part of Toby's December. basically QX use to and QX, full by early beginning from go to our that the

all very faculty on part our this We way PrevU going the PrevU trained low early a experience as That for more think the physicians training folks group part program. product, early best will part be on in number. the that centers. group launch. will national much be in we're That in again, So the of to will those get track. launch in of be We've environment hundreds will phase will of come December much controlled that coming that the that's as the with be of through setting PrevU launch the and of

to offer training launch. will on bring move As as variety part that we options of we full those of commercial the accounts we forward, different a

training that a we integration outcomes we first for can there'll there virtual we similar setting with be and be training more There'll what clinical again controlled have in we optimize or national be did move training and so options, again, Collection. will think -- much that office important options, options. will RHA very practice very to this forward. in as that we phase, of Some it's practice be in But

post looks So launch the at do accounts that like. session. obviously update it's obviously, Again, premature accounts QX, full QX as that early with. a we closely look to you, so more introduction what But existing and we we'll in running with running very QX, those through an plan from starting we relationship feedback in December, have have to commercial it's PrevU little into work

Operator

And our Amsellem David question comes next Piper from with Sandler.

David Amsellem

couple. a just So

of sales force headcount you greater the can the about in of number criteria an just talk you us for a the and force -- remind when on expanding if first, And I sizing, practices. ultimately guess, targeting some So expansion of have overtime the or sales cards?

a the XXXX, thinking DAXXIFY, direct-to-consumer number launch secondly, And help I a how regarding So but you for the just one. you're efforts methodical us DAXXIFY? doctors point more strategy you that's But then in on in what full initiatives, do second really quarter, that as and you've understand you bore have not think launch know about longer trained. getting go DTC about at out laid term. fulsome

Mark Foley

it sizing the sales Dustin type second expansion criteria, Thanks, one then and over that turn around David. about to take DTC Maybe I'll to of and stuff. talk force

a about from talked level. DTC focused really the strategy, perspective, So account at long prestige our we've

we positioned focused that So of the switch part best is everything discussion believe the is The there account. on belief customer. that and they're that our training doing to we're inform education, the with that

of our choices practice level lot information early on the can And about this think the their in they them the around that so they will focused how again, the they provide then they do decisions should that to to customers make. going be may want alternative with share be making price market. ultimate at they're also that a pricing are And the to tools ones

marketing the account more a continue will So much to But of as makes our then offers. activation will today's at driven, not more we'll on account does want and much strategy sort spend not be with rely Over phase much certainly new assess initial create side DTC we at level certainly will strategy, of that digital Dustin, move we sense. with time, this maybe at be spend have to market, And that you going the phase, we you it the launch because it's assess sales level. as launch because media but judicious surround how certainly marketing hit with the more focused we a to lot the brand believe, big in be a early But and to visibility. of support consumer we'll environment, in win-win in on can But to forward. again, side product the the social the product on approaches media, that social efforts. things. different digital, the this awareness

Dustin Sjuts

sure. Yes, Thanks Mark.

I about we've think, at some of the Dave, right how you the will to knowing what's sales look talked we need force point. previously this briefly time, expand that at in terms

We've If drive value of the products you and our strategy to much grow, look have that penetration with relationships, we least as continue at we've had, of services to don't the deep accounts aspirations it is trying through amount meaning to will all over out to those the for RHA call time and really to in to XX,XXX to get talked account value around go to allow DAXXI. based space. this both that XX,XXX accounts XX,XXX to you trying on unlock

of go adding that. XXX you for now accounts revenue a analysis of the ranges one with they another as product, call for overall as a force the so over that in productivity And you well just kind of of little product, sales focused in have number through on had can

they're you're that And right the time at for of And other that going where calling of XXXX. benchmarks those would expansion, accounts. to to to be so in rep at expand, it rep XX,XXX be be for wouldn't and on which we're likely process we because point with that currently, the kind of looking competitive kind are in

in have phase will likely it here next XXXX. be of growth and So a measured

Operator

Stacy comes question with from next Lee Stifel. Our

Stacy Lee

on is matter. initially, launch quarter. wanted sharing not reordering [indiscernible] the be telling sold? of metrics about not of broad we more what how a accounts Just for the be This the metrics initial of of This should penetration may kind Stacy so many to Congratulations us about We and will number calling with prestige be know to launch accounts how here? you'll population in Annabel. trained accounts great the think the depth or you maybe DAXXIFY. Will rates

Mark Foley

Stacy. Yes. Thanks,

about RHA, the of been accounts doing we've at we've If talked number you a on with that look quarterly been what basis. onboarding we've

side. So this on accounts and quarter, obviously, last then revenue over X,XXX the

it's putting think to to metrics we're metrics talk out We on. what that about report premature different there. sure we want I a that little make

have and business to that way We anomaly of a of going represent look they're the just going they're best that forward. lot sort an to at confidence not in the

as so we we'll about we're be phase, So have get we'll to into information lot going share share. we believe Obviously, try that and PrevU be thoughtful of to this a useful and will things what be. we're in trends that But of market. and it's in exactly what that helpful early indicative think of commitments I bit the any little the make a to terms seeing we

Operator

question And with comes our next Flynn from Terence Morgan Stanley.

Justin Phillips

Justin is This Phillips Terence. on for

a thoughts run Just for with year? for the next earnings? think two preliminary can for then guidance Is good rate me. about And provide you guys the revenue planning to Are to share conjunction XQ any for you baseline XXXX in XQ regarding expense outlook next year?

Mark Foley

Yes.

this for is to Toby I'll then Mark. expense outlook. hand the one and the first it second the Justin, on take one

the launching about some to as be DAXXIFY terms launch and partner it revenue market going and how of it's filler how going premature think is the for In thinking marketplace, that we'll be from in should want feedback terms of we're platform. to now now I guidance get XXXX, that just we into with we our

probably for expense us be at revenue time side. at I'll that a of So then little familiarity we of it's enough time getting market the to probably looking some form of we'll to And be guidance. on sort performing when would that as look how let 'XX, the Hopefully, and the we end Toby, product have by 'XX, where, with better you in 'XX a hit the bit get premature. is the

Tobin Schilke

Yes.

at our provided XXXX. a end at $XXX full million guidance trailing the the million of look the million, about for OpEx, $XXX you we've If XX-month year $XXX non-GAAP at and to upper we're

all out you investment about into field When XXXX. model in force you think take can DAXXIFY. you on consideration would and to about XXXX, that continued start I So expansion when think our commentary

time. XXXX we XXXX, given in that typically early in on haven't guidance point yet We at and do that

Operator

Rohit from with Bhasin comes question next & Our Company. Needham

Rohit Bhasin

This Robin, Serge. on for is

a Just for me. couple

pricing In are share in shareholder two can how virtual DAXXIFY categories, how the in-person training to you in feedback for willingness or therapeutics plan a for for any on preferred? seen do And format terms pricing go you seeing that then differ? the value? is just the the physicians' categories aesthetics of to for maximize And will DAXXIFY what you've on you

Mark Foley

Yes.

side the and in aesthetic, charge pricing will So pricing between on we market. of market there to therapeutic therapeutics, since read-through some have the we'll an a therapeutic the in what be there's between price side. alignment the baseline aesthetics price since we aesthetic we're that linkage And launching of and the into start will ultimately develop it charge that

we so overall therapeutic how second the then question. we marketplace, the into And the as end pricing. get And on will informing up be that

Dustin Sjuts

Yes, I that. take can

terms different with we've you than more virtual willingness think where trainings that, live well to the [injection] in with we're educate for follow-ons education In and supported [RevanceULive] the to two virtually, our probably get component, dozen train same thing here live office shown RHA, at as and then and posted of I our doing we've as studio DAXXIFY.

folks not into DAXXIFY, But options. to or. an choosing the an those it's we program. say us rate I'll live think and was don't a appropriate Nashville limiter about want put really we It's for part the having that for PrevU coming So to our that

Mark Foley

up QX in is to able accounts, think these session. to early I to of was program the the versus early in in-person found December there move a in part that actually it's out lot we an reaching that participating in reason we of interest PrevU And strong were

receptivity with offer Nashville we we've So very group been the of to virtual sessions move have the this to more to through pleased travel to practice, a we as want for lot PrevU flexibility in program. and PrevU but

Operator

comes next with question Our Instructions] Prasad [Operator from Balaji Barclays.

Unidentified Analyst

This for actually [Mechila] is on Balaji.

if wondering provide on bit Just for DAXXIFY dystonia? on additional we expect therapeutics, more of progress outside of and both hear a can updates the aesthetics could to but cervical you color indications when more

Mark Foley

we reminder, received sBLA we program that. austerity X you mentioned, dystonia, when implemented as cervical some on a side, therapeutics as completed side, CRL, a We've Phase upper indication the the From for measures. spasticity. limb the filed we for the And also

So programs. initiating we additional additional enrolling stopped clinical programs clinical or

on at our lateral XXXX. what guidance have year. strat the little operating already forehead the we when And bit for color planning done So Phase for lean side, start that provide to to then more on X studies aesthetic programs are and in at the upper and face. a 'XX XXXX, in we've part beginning we in, therapeutic lines going of additional looking full we're of lines expense We'll canthal

to move with already is So Phase that's we in X whether out timing indications. and continue to or X Phase evaluate there, aesthetic the forward want we'll additional there programs data of not

that's a So well. as TBD

Operator

Q&A our you session concludes today's your and That conference Thank for call. participation.

may at time. this You disconnect

Revance Therapeutics (RVNC) 9 Nov 222022 Q3 Earnings call transcript